# Corteva, Inc.: financial statements, quarterly

CTVA · NYSE · CIK 1755672 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ctva.md) · [Financials](/companies/ctva/financials.md) · [Filings](/companies/ctva/filings.md) · [Insiders](/companies/ctva/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ctva/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,590](/filings/0001755672-24-000024.md) | [3,707 d](/filings/0001755672-26-000004.md) | [4,492](/filings/0001755672-25-000011.md) | [6,112](/filings/0001755672-25-000017.md) | [2,326](/filings/0001755672-25-000022.md) | [3,978 d](/filings/0001755672-26-000004.md) | [4,417](/filings/0001755672-26-000010.md) | [6,456](/filings/0001755672-26-000025.md) | [2,618](/filings/0001755672-25-000022.md) | [3,910 d](/filings/0001755672-26-000004.md) | [4,905](/filings/0001755672-26-000010.md) | [6,379](/filings/0001755672-26-000025.md) |
| Cost of revenue | $m | [1,646](/filings/0001755672-24-000024.md) | [2,366 d](/filings/0001755672-26-000004.md) | [2,550](/filings/0001755672-25-000011.md) | [2,918](/filings/0001755672-25-000017.md) | [1,565](/filings/0001755672-25-000022.md) | [2,496 d](/filings/0001755672-26-000004.md) | [2,342](/filings/0001755672-26-000010.md) | [2,932](/filings/0001755672-26-000025.md) | [1,644](/filings/0001755672-25-000022.md) | [2,254 d](/filings/0001755672-26-000004.md) | [2,372](/filings/0001755672-26-000010.md) | [2,718](/filings/0001755672-26-000025.md) |
| Research and development | $m | [335](/filings/0001755672-24-000024.md) | [357 d](/filings/0001755672-26-000004.md) | [332](/filings/0001755672-25-000011.md) | [357](/filings/0001755672-25-000017.md) | [348](/filings/0001755672-25-000022.md) | [365 d](/filings/0001755672-26-000004.md) | [335](/filings/0001755672-26-000010.md) | [375](/filings/0001755672-26-000025.md) | [351](/filings/0001755672-25-000022.md) | [413 d](/filings/0001755672-26-000004.md) | [341](/filings/0001755672-26-000010.md) | [388](/filings/0001755672-26-000025.md) |
| Selling, general and administrative | $m | [670](/filings/0001755672-24-000024.md) | [735 d](/filings/0001755672-26-000004.md) | [736](/filings/0001755672-25-000011.md) | [1,054](/filings/0001755672-25-000017.md) | [671](/filings/0001755672-25-000022.md) | [735 d](/filings/0001755672-26-000004.md) | [751](/filings/0001755672-26-000010.md) | [1,156](/filings/0001755672-26-000025.md) | [725](/filings/0001755672-25-000022.md) | [860 d](/filings/0001755672-26-000004.md) | [877](/filings/0001755672-26-000010.md) | [1,164](/filings/0001755672-26-000025.md) |
| Income tax | $m | [(129)](/filings/0001755672-24-000024.md) | [(92.0) d](/filings/0001755672-26-000004.md) | [106](/filings/0001755672-25-000011.md) | [282](/filings/0001755672-25-000017.md) | [(114)](/filings/0001755672-25-000022.md) | [138 d](/filings/0001755672-26-000004.md) | [117](/filings/0001755672-26-000010.md) | [422](/filings/0001755672-26-000025.md) | [(62.0)](/filings/0001755672-25-000022.md) | [7.0 d](/filings/0001755672-26-000004.md) | [133](/filings/0001755672-26-000010.md) | [408](/filings/0001755672-26-000025.md) |
| Net income | $m | [(321)](/filings/0001755672-24-000024.md) | [(253) d](/filings/0001755672-26-000004.md) | [419](/filings/0001755672-25-000011.md) | [1,053](/filings/0001755672-25-000017.md) | [(524)](/filings/0001755672-25-000022.md) | [(41.0) d](/filings/0001755672-26-000004.md) | [652](/filings/0001755672-26-000010.md) | [1,314](/filings/0001755672-26-000025.md) | [(320)](/filings/0001755672-25-000022.md) | [(552) d](/filings/0001755672-26-000004.md) | [720](/filings/0001755672-26-000010.md) | [1,161](/filings/0001755672-26-000025.md) |
| Diluted EPS | $ per share | [(0.45)](/filings/0001755672-24-000024.md) | not reported | [0.60](/filings/0001755672-25-000011.md) | [1.51](/filings/0001755672-25-000017.md) | [(0.76)](/filings/0001755672-25-000022.md) | not reported | [0.95](/filings/0001755672-26-000010.md) | [1.92](/filings/0001755672-26-000025.md) | [(0.47)](/filings/0001755672-25-000022.md) | not reported | [1.07](/filings/0001755672-26-000010.md) | [1.73](/filings/0001755672-26-000025.md) |
| Basic EPS | $ per share | [(0.45)](/filings/0001755672-24-000024.md) | not reported | [0.60](/filings/0001755672-25-000011.md) | [1.51](/filings/0001755672-25-000017.md) | [(0.76)](/filings/0001755672-25-000022.md) | not reported | [0.95](/filings/0001755672-26-000010.md) | [1.92](/filings/0001755672-26-000025.md) | [(0.47)](/filings/0001755672-25-000022.md) | not reported | [1.07](/filings/0001755672-26-000010.md) | [1.73](/filings/0001755672-26-000025.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [2.3](/filings/0001755672-24-000024.md) | [2.6](/filings/0001755672-25-000005.md) | [1.5](/filings/0001755672-25-000011.md) | [1.8](/filings/0001755672-25-000017.md) | [2.4](/filings/0001755672-25-000022.md) | [3.1](/filings/0001755672-26-000004.md) | [2.0](/filings/0001755672-26-000010.md) | [2.1](/filings/0001755672-26-000025.md) | [2.5](/filings/0001755672-25-000022.md) | [4.5](/filings/0001755672-26-000025.md) | [2.0](/filings/0001755672-26-000010.md) | [2.4](/filings/0001755672-26-000025.md) |
| Current assets | $bn | [16.3](/filings/0001755672-24-000024.md) | [16.3](/filings/0001755672-25-000005.md) | [17.2](/filings/0001755672-25-000011.md) | [15.4](/filings/0001755672-25-000017.md) | [15.6](/filings/0001755672-25-000022.md) | [15.1](/filings/0001755672-26-000004.md) | [16.6](/filings/0001755672-26-000010.md) | [16.0](/filings/0001755672-26-000025.md) | [16.4](/filings/0001755672-25-000022.md) | [17.3](/filings/0001755672-26-000025.md) | [17.4](/filings/0001755672-26-000010.md) | [16.4](/filings/0001755672-26-000025.md) |
| Total assets | $bn | [43.1](/filings/0001755672-24-000024.md) | [43.0](/filings/0001755672-25-000005.md) | [43.6](/filings/0001755672-25-000011.md) | [41.5](/filings/0001755672-25-000017.md) | [41.9](/filings/0001755672-25-000022.md) | [40.8](/filings/0001755672-26-000004.md) | [42.1](/filings/0001755672-26-000010.md) | [41.8](/filings/0001755672-26-000025.md) | [42.2](/filings/0001755672-25-000022.md) | [42.8](/filings/0001755672-26-000025.md) | [42.7](/filings/0001755672-26-000010.md) | [41.6](/filings/0001755672-26-000025.md) |
| Current liabilities | $bn | [10.3](/filings/0001755672-24-000024.md) | [10.4](/filings/0001755672-25-000005.md) | [11.3](/filings/0001755672-25-000011.md) | [9.0](/filings/0001755672-25-000017.md) | [10.4](/filings/0001755672-25-000022.md) | [10.4](/filings/0001755672-26-000004.md) | [11.5](/filings/0001755672-26-000010.md) | [9.5](/filings/0001755672-26-000025.md) | [10.4](/filings/0001755672-25-000022.md) | [12.1](/filings/0001755672-26-000025.md) | [11.9](/filings/0001755672-26-000010.md) | [10.8](/filings/0001755672-26-000025.md) |
| Current portion of debt | $bn | [0.2](/filings/0001755672-24-000024.md) | [0.2](/filings/0001755672-25-000005.md) | [0.0](/filings/0001755672-25-000011.md) | [0.0](/filings/0001755672-25-000017.md) | [0.5](/filings/0001755672-25-000022.md) | [0.5](/filings/0001755672-26-000004.md) | [0.7](/filings/0001755672-26-000010.md) | [1.3](/filings/0001755672-26-000025.md) | [0.8](/filings/0001755672-25-000022.md) | [0.8](/filings/0001755672-26-000025.md) | [0.8](/filings/0001755672-26-000010.md) | [0.0](/filings/0001755672-26-000025.md) |
| Shareholders' equity | $bn | [25.2](/filings/0001755672-24-000024.md) | [25.0](/filings/0001755672-25-000005.md) | [24.8](/filings/0001755672-25-000011.md) | [25.2](/filings/0001755672-25-000017.md) | [24.7](/filings/0001755672-25-000022.md) | [23.8](/filings/0001755672-26-000004.md) | [24.3](/filings/0001755672-26-000010.md) | [25.9](/filings/0001755672-26-000025.md) | [25.2](/filings/0001755672-25-000022.md) | [24.1](/filings/0001755672-26-000025.md) | [24.4](/filings/0001755672-26-000010.md) | [25.2](/filings/0001755672-26-000025.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(105) d](/filings/0001755672-24-000024.md) | [4,373 d](/filings/0001755672-26-000004.md) | [(2,609)](/filings/0001755672-25-000011.md) | [451 d](/filings/0001755672-25-000017.md) | [130 d](/filings/0001755672-25-000022.md) | [4,173 d](/filings/0001755672-26-000004.md) | [(2,109)](/filings/0001755672-26-000010.md) | [947 d](/filings/0001755672-26-000025.md) | [193 d](/filings/0001755672-25-000022.md) | [4,375 d](/filings/0001755672-26-000004.md) | [(2,891)](/filings/0001755672-26-000010.md) | [(466) d](/filings/0001755672-26-000025.md) |
| Capital expenditure | $m | [162 d](/filings/0001755672-24-000024.md) | [183 d](/filings/0001755672-26-000004.md) | [148](/filings/0001755672-25-000011.md) | [114 d](/filings/0001755672-25-000017.md) | [154 d](/filings/0001755672-25-000022.md) | [181 d](/filings/0001755672-26-000004.md) | [94.0](/filings/0001755672-26-000010.md) | [118 d](/filings/0001755672-26-000025.md) | [157 d](/filings/0001755672-25-000022.md) | [222 d](/filings/0001755672-26-000004.md) | [81.0](/filings/0001755672-26-000010.md) | [122 d](/filings/0001755672-26-000025.md) |
| Dividends paid | $m | [114 d](/filings/0001755672-24-000024.md) | [112 d](/filings/0001755672-26-000004.md) | [112](/filings/0001755672-25-000011.md) | [111 d](/filings/0001755672-25-000017.md) | [117 d](/filings/0001755672-25-000022.md) | [118 d](/filings/0001755672-26-000004.md) | [116](/filings/0001755672-26-000010.md) | [116 d](/filings/0001755672-26-000025.md) | [122 d](/filings/0001755672-25-000022.md) | [121 d](/filings/0001755672-26-000004.md) | [121](/filings/0001755672-26-000010.md) | [120 d](/filings/0001755672-26-000025.md) |
| Share repurchases | $m | [253 d](/filings/0001755672-24-000024.md) | [171 d](/filings/0001755672-26-000004.md) | [252](/filings/0001755672-25-000011.md) | [252 d](/filings/0001755672-25-000017.md) | [253 d](/filings/0001755672-25-000022.md) | [252 d](/filings/0001755672-26-000004.md) | [270](/filings/0001755672-26-000010.md) | [250 d](/filings/0001755672-26-000025.md) | [250 d](/filings/0001755672-25-000022.md) | [301 d](/filings/0001755672-26-000004.md) | [250](/filings/0001755672-26-000010.md) | [250 d](/filings/0001755672-26-000025.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [719](/filings/0001755672-23-000025.md) | [716](/filings/0001755672-24-000013.md) | [714](/filings/0001755672-24-000019.md) | [708](/filings/0001755672-24-000024.md) | [703](/filings/0001755672-25-000011.md) | [698](/filings/0001755672-25-000017.md) | [691](/filings/0001755672-25-000022.md) | [687](/filings/0001755672-26-000010.md) | [683](/filings/0001755672-26-000025.md) | [679](/filings/0001755672-25-000022.md) | [674](/filings/0001755672-26-000010.md) | [670](/filings/0001755672-26-000025.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 667,196,000 at 2026-07-24, from the cover of the [10-Q filed 2026-07-31](/filings/0001755672-26-000025.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.